Category Specific RSS

myelofibrosis

Aussie cancer researcher primed for 2023 with groundbreaking clinical trial data releases scheduled

Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly…

3 years ago

Pharmaxis cancer drug progress detailed at leading scientific conference, eyes FDA discussions in 2023

Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer,…

3 years ago

Platinum Asset Management identify value opportunity in Pharmaxis with $1.9m stake

When it comes to biotech investing, the value opportunities in Australia attract many of the world's smartest investors. Amongst them,…

3 years ago

Encouraging myelofibrosis interim data sets Pharmaxis towards treating incurable disease

For patients given less than five years to live after being diagnosed with myelofibrosis, there is a new flicker of…

3 years ago

Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial

This morning’s announcement may have surprised many investors following the Pharmaxis (ASX: PXS) story because where on earth does Parkinson’s…

3 years ago